MedTrace Logo

Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients

NCT03601143 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-10-20

No results posted yet for this study

Summary

This study will prospectively compare liquid-biopsy based methods for prediction of resistance under androgen-receptor signaling inhibitors. The main goal is to determine the optimal method to determine androgen-receptor variant 7 (AR-V7) status. In addition, the investigators will explore novel other, AR-V7 independent mechanisms of resistance and their predictive value for proper treatment. These are based on further AR splice variants, and on neuroendocrine differentiation of prostate cancer cells.

Conditions

  • Castration-resistant Prostate Cancer

Interventions

OTHER

Blood samples prior to a new line of AR-targeted therapy

Blood will be drawn at baseline prior to a new line of AR-targeted therapy.

Sponsors & Collaborators

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Matthias M Heck, MD · Technical University of Munich

  • Christof Winter, MD PhD · Technical University of Munich

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2023-06-30
Completion
2024-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03601143 on ClinicalTrials.gov